Single-dose Study to Evaluate Safety, Tolerability, and Pharmacodynamics of REMD-477 in Subjects With Type 1 Diabetes Mellitus
PHASE1CompletedINTERVENTIONAL
Enrollment
21
Participants
Timeline
Start Date
March 31, 2016
Primary Completion Date
January 31, 2017
Study Completion Date
January 31, 2017
Conditions
Type 1 Diabetes MellitusDiabetes
Interventions
BIOLOGICAL
REMD-477
BIOLOGICAL
Placebo Comparator
Trial Locations (2)
Unknown
San Diego
St Louis
All Listed Sponsors
lead
REMD Biotherapeutics, Inc.
INDUSTRY
NCT02715193 - Single-dose Study to Evaluate Safety, Tolerability, and Pharmacodynamics of REMD-477 in Subjects With Type 1 Diabetes Mellitus | Biotech Hunter | Biotech Hunter